Shots: The PHYOX 3 OLE study involves assessing of nedosiran in participants aged ≥6yrs. with PH1 or PH2 who have participated in any previous PHYOX clinical development program trial as […]readmore
Tags : Evaluating
Shots: The two P-III studies (ENHANCE-1 & ENHANCE-2) will assess the efficacy and safety of nebulized ensifentrine (3mg, bid) as monothx. and added onto a single bronchodilator either a LAMA/ […]readmore
Shots: Zydus has commenced the adaptive P-I/II human clinical trials of its plasmid DNA vaccine, ZyCoV-D and reported its first human dosing The Adaptive P-I/II dose escalation study will assess […]readmore
Shots: Zydus’ ZyCoV-D has completed the preclinical studies and has received DCGI approval to initiate P-I/II human clinical trials in India. In its preclinical study, the vaccine demonstrated that it […]readmore
Shots: Bharat Biotech has received DCGI approval to conduct P-I & II clinical studies assessing Covaxin, developed in collaboration with ICMR and NIV. The company anticipate initiating the clinical studies […]readmore
COVID-19
Pharma
Fulcrum Initiates P-III LOSVID Study Evaluating Losmapimod for Patients Hospitalized
Shots: The P-III LOSVID study assess the safety and efficacy of losmapimod (15mg, bid) vs PBO for 14 days on top of SOC in ~400 patients hospitalized with COVID-19 and […]readmore
Shots: FibroGen initiates the P-II study assessing the efficacy and safety of pamrevlumab vs SOC in hospitalized patients in a ratio (1:1) with acute COVID-19 across the US and is […]readmore
Shots: Following the US FDA’s approval, Gilead will screen healthy volunteers for P-I study this week and plans to initiate the study in patients with COVID-19 in Aug’2020. The therapy […]readmore
Shots: Novartis has discontinued its clinical trial HCQs due to feasibility of recruitment. The recruitment challenge has made it unlikely that the clinical team will be able to collect meaningful […]readmore
Shots: RedHill has submitted CTA to the MHRA and AIFA for a P-II/III study evaluating opaganib vs PBO along with SOC in patients hospitalized with severe COVID-19. The P-II/III study […]readmore